Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1787-1797

  Welt, S ^a   Scott, A M ^a   Divgi, C R ^a   Kemeny, N E ^a   Finn, R D ^a   Daghighian, F ^a   Germain, J S ^a   Richards, E C ^a   Larson, S M ^a   Old, L J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARMUSTINE; CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IODINE 125; LEVAMISOLE; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33; RECOMBINANT INTERLEUKIN 1; STREPTOZOCIN; TOPOTECAN; TRIMETREXATE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; THROMBOCYTOPENIA;

EID: 8944220716     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1787     Document Type: Article

References (29)

1. Welt S, Divgi CR, Real FX, et al: Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study of monoclonal antibody A33. J Clin Oncol 8:1894-1906, 1990
2. Welt S, Divgi CR, Kemeny N, et al: Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12:1561-1571, 1994
3. 111Inmonoclonal antibody A33 to human colon cancer transplants in nu/ nu mice. Proc Am Assoc Cancer Res 34:476, 1993 (abstr)
4. 131I-monoclonal antibody A33. Proc Am Assoc Cancer Res 34:477, 1994 (abstr)
5. 125I-labeled A33 monoclonal antibody across the cytosol by vesicular internalization. J Nucl Med (in press)
6. 131iodine. Radiat Res 47:94-109, 1971
7. 3HTdR. Radiat Res 67:332-343, 1976
8. Kassis AI, Howell RW, Sastry KSR, et al: Positional effects of Auger decays in mammalian cells in culture, in Baverstock KF, Charlton DE (eds): DNA Damage by Auger Emitters. London, United Kingdom, Taylor & Francis, 1988, pp 1-14
9. Humm JL: Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490-1497, 1986
10. Howell RW: Radiation spectra for Auger-electron emitting radionuclides: Report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 19:1371-1383, 1992
11. Humm JL, Howell RW, Rao DV: Dosimetry for Auger electron emitters: Report No. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 21:1901-1915, 1994
12. Brady LW, Markoe AM, Woo VD, et al: Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforma. Front Radiat Ther Oncol 24:151-160, 1990
13. 125I labeled monoclonal antibody against epidermal growth factor receptor. Antibody Immunoconj Radiopharm 3:169-175, 1990
14. Kemeny N, Yagoda A, Braun D Jr: Metastatic colorectal carcinoma: A prospective randomized trial of methyl-CCNU, 5-fluorouracil (5-FU) and vincristine (MOD) versus MOF plus streptozotocin (MOF-Strep). Cancer 51:20-24, 1983
15. Meredith RF, LoBuglio AF, Plott WE, et al: Pharmacokinetics, immune response and biodistribution of 131-I-labeled chimeric mouse/human IgG1 k, 17-1A monoclonal antibody. J Nucl Med 32:1162-1168, 1991
16. Aitken DR, Hinkle GH, Thurston MO, et al: A gamma detecting probe for radioimmune detection of CEA-producing tumours: Successful experimental use and clinical case report. Dis Colon Rectum 27:279-282, 1984
17. Martin EW Jr, Minton JP, Carey LC: CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal cancer. Ann Surg 202:310-317, 1985
18. Martin EW Jr, Mojzisik CM, Hinkle GH Jr, et al: Radioimmunoguided surgery using monoclonal antibody. Am J Surg 156:386-32, 1988
19. Cohen AM, Martin EW, Lavery I, et al: Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 126:349-352, 1991
20. Arnold MW, Schneebaum S, Berens A, et al: Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 216:627-632, 1992
21. Weiner LM, Steplewski Z, Koprowski H, et al: Divergent dose-related effects of γ-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocyte. Cancer Res 48:1042-1046, 1988
22. Weiner LM, Moldofsky PJ, Gatenby RA, et al: Antibody delivery and effector cell activation in a phase II trial or recombinant γ-interferon and the murine monoclonal antibody C017-1A in advanced colorectal carcinoma. Cancer Res 48:2568-2573, 1988
23. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343:1177-1183, 1994
24. 2). Int J Cancer 48:344-349, 1991
25. Fagerberg J, Hjelm A-L, Ragnhammar P, et al: Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 55:1824-1827, 1995
26. Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312:1465-1472, 1985
27. Fisher B, Wolmark N, Rockette H, et al: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 80:21-29, 1988
28. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
29. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994